Other atherogenic measures moved in parallel
In contrast, no significant difference was observed in AKT mRNA expression among the experimental groups (KruskalWallis H = 5.947, p = 0.114
Cardiovascular safety has been thoroughly evaluated, with trials demonstrating not only safety but also significant cardiovascular benefits
Once patients get to mid to high doses of 8 to 12 mg, costs rise precipitously
These include: Localised redness (erythema) Swelling or induration at the injection site Bruising or haematoma formation Itching (pruritus) around the injection area Mild pain or tenderness following administration These reactions are broadly consistent with those seen with other subcutaneously administered incretin therapies
Until then, the most accurate answer is: Retatrutide is the higher-upside candidate, while CagriSema is the more incremental combination strategy